Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma

Leuk Lymphoma. 2021 Dec;62(12):3063-3065. doi: 10.1080/10428194.2021.1950711. Epub 2021 Jul 13.

Authors

Leopoldine Lapierre¹, Sarah Pericart², Caroline Protin¹, Cecile Borel¹, Loic Ysebaert¹, Camille Laurent², Lucie Oberic¹

Affiliations

¹ Department of Hematology, Institut Universitaire du Cancer Toulouse-Oncopole, CHU de Toulouse, France.
² Department of Pathology, Institut Universitaire du Cancer Toulouse-Oncopole, CHU de Toulouse, France.

PMID: 34254883
DOI: 10.1080/10428194.2021.1950711

No abstract available

Publication types

Letter

MeSH terms

Brentuximab Vedotin
Hodgkin Disease* / diagnosis
Hodgkin Disease* / drug therapy
Hodgkin Disease* / pathology
Humans
Immunoconjugates*
Neoplasm Recurrence, Local / drug therapy
Nivolumab / therapeutic use

Substances

Immunoconjugates
Nivolumab
Brentuximab Vedotin